FANCL

FA complementation group L

Explore in graph →CI-GENE-00001616HGNC:20748 ENSG00000115392 NCBI 55120 CIViC Approved

Curated evidence

Clinical evidence (1)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
FANCL Mutation1
Olaparib	Castration-Resistant Prostate Carcinoma	Predictive	A	Supports Sensitivity Response	1	submitted	EID11211 This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a n… (full text at CIViC) PMID 32343890 · de Bono et al., 2020 · Open in CIViC	civic

Cohorts

Alteration frequency by cohort (6)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved6 cohort rows · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Chronic Lymphocytic Leukemia (MSK, 2026) cllsll_msk_2026	Small Lymphocytic Lymphoma	Ssm	5	19	26.3%	11

Literature

Linked publications (0)

Data not yet available

No publication linked to this gene yet.